Z. Younossi

发表

Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan

M. Mizokami, Y. Eguchi, Z. Younossi, 2018, Journal of viral hepatitis.

Gene expression profiles associated with anaemia and ITPA genotypes in patients with chronic hepatitis C (CH‐C)

M. Stepanova, Z. Younossi, A. Birerdinc, 2012, Journal of viral hepatitis.

Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe

G. Cooke, Z. Younossi, P. Buggisch, 2018, Journal of viral hepatitis.

Vietnamese community screening for hepatitis B virus and hepatitis C virus

M. Stepanova, M. Srishord, J. Kallman, 2011, Journal of viral hepatitis.

The impact of chronic hepatitis C on resource utilisation and in‐patient mortality for Medicare beneficiaries between 2005 and 2010

M. Stepanova, L. Henry, Z. Younossi, 2013, Alimentary pharmacology & therapeutics.

Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH‐C) patients: an economic model from five European countries

M. Buti, M. Stepanova, S. Mauss, 2016, Journal of viral hepatitis.

Sofosbuvir and ledipasvir improve patient‐reported outcomes in patients co‐infected with hepatitis C and human immunodeficiency virus

M. Stepanova, L. Henry, Z. Younossi, 2016, Journal of viral hepatitis.

A meta‐analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection

M. Stepanova, L. Henry, A. Adeyemi, 2015, Journal of viral hepatitis.

Systematic review with meta‐analysis: non‐alcoholic steatohepatitis ‐ a case for personalised treatment based on pathogenic targets

L. Henry, Z. Younossi, A. Mishra, 2014, Alimentary pharmacology & therapeutics.

Differential expression of miRNAs in the visceral adipose tissue of patients with non‐alcoholic fatty liver disease

A. Baranova, Z. Goodman, Z. Younossi, 2010, Alimentary pharmacology & therapeutics.

Systematic review: patient‐reported outcomes in chronic hepatitis C ‐ the impact of liver disease and new treatment regimens

L. Henry, Z. Younossi, Z. Younossi, 2015, Alimentary pharmacology & therapeutics.

Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults

A. Baranova, Z. Younossi, G. Vernon, 2011, Alimentary pharmacology & therapeutics.

Knowledge about infection is the only predictor of treatment in patients with chronic hepatitis C

M. Stepanova, Z. Younossi, M. Afendy, 2013, Journal of viral hepatitis.

The impact of type 2 diabetes and obesity on the long‐term outcomes of more than 85 000 liver transplant recipients in the US

S. Saab, M. Stepanova, L. Henry, 2014, Alimentary pharmacology & therapeutics.

Quality of life in adolescents with hepatitis C treated with sofosbuvir and ribavirin

M. Stepanova, L. Henry, Z. Younossi, 2018, Journal of viral hepatitis.

The impact of hepatitis C burden: an evidence‐based approach

W. Kim, H. El‐Serag, S. Saab, 2014, Alimentary pharmacology & therapeutics.

Functional pathway analysis of genes associated with response to treatment for chronic hepatitis C

M. Stepanova, G. Manyam, A. Birerdinc, 2010, Journal of viral hepatitis.

Long‐term trends in chronic hepatitis B virus infection associated liver transplantation outcomes in the United States

S. Saab, Z. Younossi, R. Wong, 2017, Journal of viral hepatitis.

Adipokines and cytokines in non‐alcoholic fatty liver disease

A. Baranova, B. Ranard, Z. Goodman, 2007, Alimentary pharmacology & therapeutics.

Cost‐effectiveness of all‐oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection

D. Dieterich, S. Saab, Haesuk Park, 2015, Alimentary pharmacology & therapeutics.

Presence of hepatitis C (HCV) infection in Baby Boomers with Medicare is independently associated with mortality and resource utilisation

Z. Younossi, M. Wymer, P. Golabi, 2016, Alimentary pharmacology & therapeutics.

Moderate, excessive or heavy alcohol consumption: each is significantly associated with increased mortality in patients with chronic hepatitis C

M. Stepanova, Z. Younossi, C. Venkatesan, 2013, Alimentary pharmacology & therapeutics.

The association of hepatitis C virus infection and post‐liver transplant diabetes: data from 17 000 HCV‐infected transplant recipients

S. Saab, M. Stepanova, L. Henry, 2015, Alimentary pharmacology & therapeutics.

Associations of chronic hepatitis C with metabolic and cardiac outcomes

M. Stepanova, Z. Younossi, E. Elsheikh, 2013, Alimentary pharmacology & therapeutics.

Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels

L. Gerber, M. Stepanova, Z. Younossi, 2015, Journal of viral hepatitis.

Long‐term outcomes of lung transplant recipients with hepatitis C infection: a retrospective study of the U.S. transplant registry

R. Wong, S. Saab, M. Stepanova, 2016, Alimentary pharmacology & therapeutics.

J. Kao, M. Stepanova, L. Henry, 2017 .

Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO network

B. Bacon, D. Dieterich, N. Tsai, 2016, Journal of viral hepatitis.

Editorial: probiotics in NASH – more studies are needed

Z. Younossi, J. Ong, Z. Younossi, 2014, Alimentary pharmacology & therapeutics.